The transcription factor CCAAT/enhancer-binding protein delta (C/EBP␦, CEBPD) is a tumor suppressor that is downregulated during breast cancer progression but may also promote metastasis. Here, we have investigated the mechanism(s) regulating C/EBP␦ expression and its role in human breast cancer cells. We describe a novel pathway by which the tyrosine kinase Src downregulates C/EBP␦ through the SIAH2 E3 ubiquitin ligase. Src phosphorylates SIAH2 in vitro and leads to tyrosine phosphorylation and activation of SIAH2 in breast tumor cell lines. SIAH2 interacts with C/EBP␦, but not C/EBP␤, and promotes its polyubiquitination and proteasomal degradation. Src/SIAH2-mediated inhibition of C/EBP␦ expression supports elevated cyclin D1 levels, phosphorylation of retinoblastoma protein (Rb), motility, invasive properties, and survival of transformed cells. Pharmacological inhibition of Src family kinases by SKI-606 (bosutinib) induces C/EBP␦ expression in an SIAH2-dependent manner, which is necessary for "therapeutic" responses to SKI-606 in vitro. Ectopic expression of degradation-resistant mutants of C/EBP␦, which do not interact with SIAH2 and/or cannot be polyubiquitinated, prevents full transformation of MCF-10A cells by activated Src (Src truncated at amino acid 531 [Src-531]) in vitro. These data reveal that C/EBP␦ expression can be regulated at the protein level by oncogenic Src kinase signals through SIAH2, thus contributing to breast epithelial cell transformation.
T
he transcription factor CCAAT/enhancer binding protein delta (C/EBP␦, CEBPD, or NFIL-6␤) exhibits many tumor suppressor-like activities. In vitro, C/EBP␦ inhibits the growth of tumor cell lines (20, 29, 45) , promotes genomic stability of mouse embryo fibroblasts (MEF) (28) , and downregulates expression of cyclin D1 (3, 20, 47) . Using a mouse model of mammary tumorigenesis, we have shown that, consistent with a tumor suppressor function, loss of C/EBP␦ increased tumor incidence. However, distant metastases to the lung were reduced in the absence of C/EBP␦, suggesting additional tumor-promoting activity by C/EBP␦ in this animal model (7) . In meningiomas, C/EBP␦ expression correlates with a low histological grade and progressionfree patient survival (8) , and CEBPD was in a 70-gene signature predicting longer survival of breast cancer patients (43) . Indeed, C/EBP␦ expression is downregulated in several types of cancers including cervix, liver, and breast (3, 38, 44, 48, 49, 60) .
Interestingly, the C/EBP␦ gene promoter can be activated by the STAT3 transcription factor (13, 61, 72) . However, STAT3 is frequently hyperactivated in cancer and is a well-characterized tumor-promoting factor (58) . Thus, we were interested in understanding how activation of STAT3 signaling in breast cancer was compatible with downregulation of C/EBP␦ in the same disease. Although the CEBPD gene was found to be methylated in a significant number of acute myelomonocytic leukemias, cervical and hepatocellular carcinomas, and a subset of breast tumors (3, 20, 38, 60) , the sporadic pattern of methylation in breast tumors suggested that other mechanisms of repression exist. Therefore, we hypothesized that signaling pathways upstream of or parallel to STAT3 lead to inhibition of C/EBP␦ expression in a manner that is dominant over activated STAT3. Because the c-myc protooncogene was shown to inhibit CEBPD promoter activity in a mouse mammary epithelial cell line (72) and because both STAT3 and c-myc can be activated by Src kinase signaling (1, 58), we investigated whether Src kinase signaling regulates C/EBP␦ expression in breast epithelial cells.
Src and the related proteins Fyn and Yes form a subfamily of cytoplasmic tyrosine kinases that transmit signals from receptor tyrosine kinases, G-protein-coupled receptors, and integrins. Hence, these kinases are central mediators in multiple signaling pathways and regulate very diverse physiological processes (11, 66) . Src family kinases are frequently overexpressed or highly activated in tumor tissues and are associated with progression of cancer (66) . Aberrant activation of c-Src regulates many functions in tumor cells such as cell proliferation, cell-cell adhesion and motility, tumor cell migration, invasion, and metastasis (23, 53, 66) . Therefore, inhibitors of Src family kinases such as dasatinib less indicated otherwise. Scramble control oligonucleotides were used in all experiments for the negative control.
Real-time PCR. Total RNA was extracted by TRIzol (Invitrogen), DNase I treated, and purified by RNAeasy (Qiagen). Two micrograms of RNA was used to make the cDNA with Superscript Reverse Transcriptase III (Invitrogen) according to the manufacturer's instructions. PCR was conducted with TaqMan gene expression primer/probe sets using a 7500 Fast Real Time PCR instrument (Applied Biosystems). Analysis was performed using the MxPro software (Stratagene). All reactions were performed in duplicates. The relative expression level of C/EBP␦ (Hs00270931_s1; Applied Biosystems) was measured using the relative quantitation ⌬⌬C T (where C T is threshold cycle) method and normalized to ␤-actin (Hs99999903_m1; Applied Biosystems). Data are from three independent samples (means Ϯ standard errors of the means [SEM] ) and were normalized to ␤-actin.
Luciferase reporter assay. The C/EBP␦ promoter (Ϫ2000 to ϩ42) was isolated by PCR from a human bacterial artificial chromosome (BAC) using the following primers: hd-2000forward, AAGCTAGCGATGTGCG TAAGTCCACACTCTATGC; hdϩ42reverse, ATAAGCTTGGCGGCGT CGGGCCGGGCTCTGCG.
The fragment was cloned into pGL4.12 by NheI and HindIII. Cells were transfected with 200 ng of either the C/EBP␦ reporter or a cyclin D1 reporter construct (Ϫ1745CD1LUC [5] ), together with 200 ng of either vector or Src Y529F (Src with a Y529F mutation) expression constructs and with 200 ng of pRSV ␤-galactosidase (␤-Gal) expression constructs as an internal control. The cells were lysed in reporter lysis buffer (Promega) and analyzed for luciferase activity per the manufacturer's instructions. ␤-Galactosidase activity was assayed with O-nitrophenyl-␤-Dgalactopyranoside as a substrate as described previously (47) and used to normalize for the variations in transfection efficiencies. Data are from three independent experiments performed in duplicate.
Western blotting and antibodies. All Western analyses are with whole-cell lysates unless indicated otherwise. Cells were lysed in SDS sample buffer or in 1ϫ reporter lysis buffer (catalog number E397A; Promega) with protease inhibitors: 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 l/ml each of phosphatase inhibitor I (P2850; Sigma), phosphatase inhibitor II (P5726; Sigma), and protease inhibitor cocktail (P8340; Sigma). Proteins were resolved on SDS-PAGE gels, and blotted onto Protran nitrocellulose membranes (Schleicher & Schuell). Membranes were blocked with bovine serum albumin (BSA) in 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.5% Tween 20 (TBS-T). Immunostaining was performed in TBS-T and visualized with Lumiglo Reserve Chemiluminescence reagent (KPL Inc.) according to the manufacturer's instructions. Antibodies were from Lab Vision Corporation Inc. (cyclin D1, catalog number RB-010-P0), Santa Cruz Biotechnology, Inc. (␤-actin, sc-1616; C/EBP␤, sc-7962; SIAH1, Sc-5505; SIAH2, sc-5507; CEBP␤, Sc-7962; pRB, sc-12901; MDM2, sc-965; PTEN, sc-133197), Abcam (retinoblastoma protein [Rb], Ab6075); BD Biosciences Pharmingen (C/EBP␦, BD69320, or BD69319 mouse monoclonal antibodies against the amino terminal 140 amino acids of human C/EBP␦), Rockland Immunologicals, Inc. (C/EBP␦, 600-401-A61; tubulin, 600-401-880), Millipore (phosphotyrosine, 05-1050), Pierce (anti-mouse and anti-rabbit horseradish peroxidase [HRP]-conjugated IgG, 1858413 and 1858415), Cell Signaling (Src, 2110; p-Src, 2101S; p53, 2524), Bethyl Laboratories, Inc. (Flag, F3165),Thermo Scientific (anti-goat HRP-conjugated IgG, 31400), and 9E10 ascites fluid (anti-myc). The pan-C/EBP rabbit antibody used to analyze the chimeric proteins recognizes a conserved sequence in the C/EBP family basic region (67) . Tubulin was used as loading control.
Coimmunoprecipitation assay. Cells were lysed in 30 mM Tris, pH 8.0, 75 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, and protease and phosphatase inhibitors. One milligram of protein lysate was mixed with 5 g of antibody and rotated overnight at 4°C. An equivalent aliquot of lysate used for specific antibodies as indicated was used for immunoprecipitation (IP) with IgG as a negative control. Protein A/G beads were blocked with 1% BSA and 1 mg/ml single-stranded DNA (ssDNA) overnight. Forty microliters of preblocked beads was added to the lysate and antibody mixture for 4 h at 4°C before centrifugation at 3,000 rpm (Eppendorf) for 30 s, followed by five washes with lysis buffer. Forty microliters of preboiled sample buffer (Bio-Rad) was then added in each IP mixture and denatured at 100°C for another 5 min. Ten microliters of each IP product was loaded. For immunoprecipitation under denatured conditions, cells were lysed in denaturing lysis buffer (50 mM Tris, pH 7.5, 70 mM ␤-mercaptoethanol) and boiled for 10 min. Four volumes of cold cell lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM Na 3 VO 4 , 1 g/ml leupeptin) was added to the previous lysate before the IP reaction.
In vitro phosphorylation analysis. SIAH2 was immunoprecipitated with anti-Flag from radioimmunoprecipitation assay (RIPA) buffer extracts of HEK293T cells transfected with Flag-SIAH2 and incubated with 1 ng of purified active Src (catalog number 14-746; Millipore) in kinase assay buffer as described previously (42) . Reactions were resolved on SDS-PAGE gels and transferred to nitrocellulose. Following autoradiography the SIAH2 bands were digested from the membrane with trypsin (and chymotrypsin as indicated in Fig. 3K ) and analyzed by reverse-phase highperformance liquid chromatography (HPLC), phosphoamino acid analysis (PAA), and Edman degradation (42) .
Cell proliferation assay. Cells were seeded in 96-well plates at 3,000 to 5,000 cells/well and treated the next day with SKI-606 as indicated in the figures. Each experiment was done with triplicate wells. Cells were incubated with 10% Alamar blue (BioSource) for 3 h, and fluorescence was quantified with a NovaStars (BMG) plate reader.
Soft-agar assay. Cells (1 ϫ 10 5 ) were suspended in medium (DMEM-F-12HAM at 1:1, containing appropriate components as described above) containing 0.3% agarose. The cell mixture was then seeded on a layer of 0.5% bottom agar in a six-well plate and allowed to grow for 2 weeks. The culture medium was changed once a week. After 2 weeks colonies were stained with Giemsa, and representative views from triplicate experiments were photographed. Colonies were counted in three independent fields at a magnification of ϫ10 for each of three independent experiments.
Cell motility assay. Cells (approximately 3 ϫ 10 5 cells/well) were seeded in culture inserts (Ibidi) and allowed to adhere for 8 to 10 h in medium containing 0.5% FBS. Culture inserts were removed using sterile tweezers, and the wall was filled with fresh medium containing 0.5% FBS.
Invasion assay. Twenty-four-well plates with precoated growth factor-reduced Matrigel (Matrigel-GFR) chambers (BD Biosciences) were prepared according to the manufacturer's instructions. The lower well of the chamber was filled with DMEM supplemented with 10% FBS. Cells were placed in the upper chamber suspended in medium containing 1% FBS at a density of 10 6 cells/ml. Following incubation for 24 h at 37°C, cells were removed from the filter top with a cotton swab, and the filter was fixed in 1% formaldehyde in phosphate-buffered saline (PBS). The cells on the bottom of the filters were stained with a Diff-Quick kit (Fisher Scientific, Pittsburgh, PA) and counted in three microscopic fields at a ϫ10 magnification per well.
Matrigel assay. MCF-10A cells were grown on Matrigel as described previously (16) . Growth factor-reduced Matrigel (354230; BD Biosciences) was added to an eight-well chamber slide and allowed to solidify for 15 to 20 min. Cells were trypsinized, washed with culture medium, and resuspended into assay medium without EGF. Cells were mixed with Matrigel-containing medium (with EGF) to get a final concentration of 5,000 cells/well in medium containing 2% Matrigel and 5 ng/ml EGF. The cells were fed with assay medium containing 2% Matrigel and 5 ng/ml EGF every 4 days.
Immunofluorescence (IF) staining of MCF-10A acini in Matrigel. The acini were immunostained at room temperature as described previously (16) . Acini were fixed using 2% paraformaldehyde for 20 min and permeabilized with 0.5% Triton X-100 for 10 min at 4°C. Cells were rinsed with PBS-glycine solution and blocked with primary blocking solution containing 130 mM NaCl, 7 mM Na 2 HPO 4 , 3.5 mM NaH 2 PO 4 , 7.7 mM NaN 3 , 0.1% bovine serum albumin, 0.2% Triton X-100, and 0.05% Tween 20 plus 10% goat serum for 1 h. The acini were next blocked with secondary blocking solution [primary blocking solution plus 20 g/ml goat anti-mouse F(ab) 2 fragment] for 40 min. Acini were then incubated with anti-laminin 5 (ab14509; Abcam), anti-active caspase-3 (ab2302; Abcam), and anti-Ki67 (Mab4190; Millipore) in the secondary blocking solution overnight at room temperature. After acini were rinsed with IF buffer (130 mM NaCl, 7 mM Na 2 HPO 4 , 3.5 mM NaH 2 PO 4 , 7.7 mM NaN 3 , 0.1% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween 20) at room temperature, they were incubated with secondary antibody (Alexa Fluor 488-conjugated goat anti-rabbit antibody [A11034; Invitrogen] or Alexa Fluor 594-conjugated goat anti-mouse antibody [A11032; Invitrogen]) for 50 min at room temperature. After acini were washed with IF buffer, they were incubated with PBS containing 4=,6=-diamidino-2-phenylindole (DAPI; 0.5 ng/ml) for 15 min. Acini were washed with PBS for 5 min and mounted with Vectashield (Vector laboratories, Inc., Burlingame, CA). Images were captured using a Zeiss Laser Scanning LSM 510.
Quantitative analyses. Quantified data are from three independent biological replicates expressed as means Ϯ SEM, unless indicated otherwise. Data were analyzed by t test or unequal variance t test with a Satterthwaite correction (see Fig. 6E and F and 7E).
RESULTS
Src kinase downregulates C/EBP␦ protein expression. We have previously shown that breast cancer cell lines express significantly less C/EBP␦ protein than untransformed breast epithelial cell lines (47) . Many breast cancer cell lines are known to contain activated Src kinase (63) , and, as expected, we found that C/EBP␦ expression inversely correlated with the phosphorylation of Src family kinases at tyrosine 419 (Fig. 1A) , which is indicative of activity (62) . The tumor cell lines MCF-7, MDA-MB-231, SKBR3, BT474, and MDA-MB-468 harbor activated endogenous Src kinases, whereas the untransformed MCF-10A and MCF-12A cells do not. These cell lines therefore reflect that Src activity is induced in breast tumors (52) . On the other hand, MCF-10A and MCF-12A cells express significantly higher levels of C/EBP␦ mRNA (44; also data not shown) and protein ( Fig. 1A ) (47) than breast tumor cell lines. Indeed, in transient cotransfection experiments, constitutively active Src downregulated a C/EBP␦ promoter-reporter construct, while the cyclin D1 promoter was induced as expected (Fig. 1B) .
To assess a causal relationship between Src activation and the reduced expression of endogenous C/EBP␦, we treated MDA-MB-231 ( Fig. 1C) and MDA-MB-468 ( Fig. 1D ) cells with the Src family kinase inhibitor SKI-606 (22) . Loss of Src phosphorylation was accompanied by induction of C/EBP␦ protein expression in these tumor cell lines. In our hands the kinetics of Src inhibition by SKI-606 was slower than previously reported (32, 63) , which could be due to differences in phosphatase activities toward Src between cell lines or in bioavailability of SKI-606 due to, e.g., efflux pumps. Surprisingly, there was no effect of SKI-606 on C/EBP␦ mRNA levels in either cell line (Fig. 1E ). Next, we tested the effect of Src activation on C/EBP␦ expression in untransformed cells. Overexpression of a constitutively activated Src truncated at amino acid 531 (Src-531) (30) in MCF-10A cells resulted in the downregulation of endogenous C/EBP␦ protein levels, whereas expression of the related protein C/EBP␤ was not affected (Fig. 1F) . Again, there was no significant effect of Src activity on C/EBP␦ mRNA levels (Fig. 1G ). Src kinase with an activating Y527F mutation (33) also downregulated C/EBP␦, while a kinase-dead K295M mutant (33) did not (Fig. 1H ). Taken together, these data show that Src kinase activity can downregulate C/EBP␦ expression by a mechanism that acts primarily at the protein level.
Src activity leads to proteasomal degradation of C/EBP␦. Next, we assessed the effect of activated Src on C/EBP␦ protein stability. Inhibition of protein synthesis by cycloheximide in MCF-10A cells revealed that C/EBP␦ was less stable when expressed in the presence of Src-531 ( Fig. 2A) . C/EBP␦ overexpression was used for this experiment in order to have detectable protein levels at the beginning of the time course with Src-531. Many proteins are turned over by proteasome-dependent degradation (18) . When MCF-10A cells were treated with the proteasome inhibitor lactacystin, endogenous C/EBP␦ expression could be rescued in the presence of Src-531 (Fig. 2B, upper panel) . In the absence of Src-531, proteasome inhibition had no significant effect on C/EBP␦ levels in MCF-10A cells. On the other hand, inhibition of the proteasome (by MG132) was sufficient to induce C/EBP␦ expression in MDA-MB-468 cells (Fig. 2B, lower panel) . Because almost all proteasome substrates are targeted for degradation by polyubiquitination, we next examined if C/EBP␦ was polyubiquitinated. C/EBP␦ has a predicted molecular mass of 28 kDa but runs at about 36 kDa on SDS-PAGE gels. Immunoprecipitation of C/EBP␦ from MCF-10A cells expressing HA-tagged ubiquitin demonstrated that Src-531 led to high-molecularweight (MW), polyubiquitinated species of C/EBP␦ (Fig. 2C) . In summary, these data show that in the presence of active Src kinase, C/EBP␦ is an unstable protein due to proteasomal degradation.
SIAH2 is necessary and sufficient for Src kinase-mediated degradation of C/EBP␦. Polyubiquitination of proteins is usually achieved by substrate-specific E3 ubiquitin ligases. SIAH2 is an E3 ligase, which is activated by the Ras signaling pathway and Src kinase (56, 70) . When we overexpressed SIAH2 in MCF-10A cells, it alone downregulated endogenous C/EBP␦ (Fig. 3A) . To address specificity for SIAH2, we also expressed MDM2 or NEDD4, which did not alter C/EBP␦ protein levels, while levels of known substrates, p53 and PTEN, respectively, decreased (Fig. 3A) . Shortterm treatment with MG132 rescued C/EBP␦ expression in the presence of SIAH2, consistent with a role of SIAH2 in targeting C/EBP␦ for proteasomal degradation (Fig. 3B) . Comparison of several human breast epithelial cell lines revealed that SIAH2 was more highly expressed in the breast tumor cell lines, especially MDA-MB-468 and MDA-MB-231, than in untransformed MCF-10A cells (Fig. 3C ). In contrast, expression of the related SIAH1 protein was more similar across these cell lines. To test the causal role of endogenous SIAH in the degradation of C/EBP␦, we inactivated the protein by two different approaches in breast cancer cells. C/EBP␦ protein expression was induced by expression of a dominant negative (DN) SIAH2 protein (4) in MDA-MD-231T or MDA-MD-468 cells (Fig. 3D) . In contrast, overexpression of SIAH1, SIAH2, or DN-SIAH1 did not induce C/EBP␦ expression (Fig. 3D) . Furthermore, depletion of SIAH2 by RNAi silencing in MDA-MB-231T cells also increased C/EBP␦ protein expression (Fig. 3E) . Importantly, Y419 phosphorylation of endogenous Src was not significantly affected by inactivation of SIAH2, ruling out such an indirect mechanism for C/EBP␦ stabilization by SIAH2 inhibition ( Fig. 3D and E) . Comparison of SIAH2 inhibition by siRNA and overexpression of DN-SIAH2 resulted in similar levels of C/EBP␦ accumulation in MDA-MB-231T cells (Fig. 3F) . Collectively, these data show that SIAH2 is necessary for constitutive C/EBP␦ degradation in breast tumor cells and is sufficient to downregulate C/EBP␦ in MCF-10A cells. Although other E3 ligases may also target C/EBP␦, the above results led us to focus our subsequent analyses on the role of SIAH2 in regulation of C/EBP␦ expression.
Next, we examined if Src could regulate SIAH2 expression. Indeed, ectopic activated Src-531 kinase induced the expression of SIAH2 in MCF-10A cells (Fig. 3G ) and, as shown before, downregulated C/EBP␦ expression. Coexpression of DN-SIAH2 attenuated downregulation of C/EBP␦ by Src-531 (Fig. 3H) . Collectively, these data show that Src-531 inhibits C/EBP␦ expression in MCF-10A cells at least in part by inducing SIAH2 expression.
Whereas Src-531 induced SIAH2 in MCF-10A cells, the Src kinase family inhibitor SKI-606 had no effect on SIAH2 expression levels in the breast tumor cell lines MDA-MB-231, MCF-7, and MDA-MB-468 (Fig. 3I) . Thus, the higher levels of SIAH2 expression in tumor cell lines (Fig. 3C ) appear independent of Src family kinase activity. MCF-7 cells contained less SIAH2 than MDA-MB-468 and MDA-MB-231 cells ( Fig. 3C and I ), which is accompanied by detectable basal levels of C/EBP␦, albeit much lower levels than those in MCF-10A and MCF-12A cells (Fig. 1) . However, Src may also regulate the activity of SIAH2. The highly homologous protein SIAH1 can be phosphorylated on at least three tyrosines. Mutation of all three tyrosines or the pharmacological Src family tyrosine kinase inhibitor PP2 blocks SIAH1-mediated ubiquitination of its target phospholipase C (PLC) (70) . Therefore, we next assessed the phosphorylation status of SIAH2. Indeed, SIAH2 was phosphorylated on tyrosine in the breast tumor cell lines, which was reduced upon SKI-606 treatment (Fig. 3I) . In response to SKI-606, C/EBP␦ expression was induced in all three cell lines shown here. In vitro kinase assays showed that Src can indeed phosphorylate SIAH2 directly (Fig.  3J ). Phosphopeptide and phosphoamino acid analysis revealed that Y86, Y140, and Y263 were targeted by Src in vitro (Fig. 3K) . The previously identified tyrosine phosphorylation sites of SIAH1 (70) correspond to amino acids (aa) 86, 239, and 263 of SIAH2. Thus, our analysis confirmed two sites and identified one new one. These data suggest that Src kinases contribute to SIAH2 activation in breast tumor cell lines by promoting its phosphorylation even though SIAH2 expression levels were not affected directly.
To assess the functional role of sites of tyrosine phosphorylation on SIAH2 activity toward C/EBP␦, we individually mutated all six tyrosine residues (aa 86, 140, 163, 166, 239, and 263) to phenylalanine. Transfection of SIAH2 variants into MCF-10A cells revealed that the sites of in vitro phosphorylation (Y86, Y140, and Y263) were indeed important for SIAH2 activity (Fig. 3L) because the mutants did not downregulate C/EBP␦ to the same extent as wild-type SIAH2. The tyrosine residues Y86 and Y140 are both essential, conceivably because they reside with the critical ring finger and Zn ϩϩ finger domains, respectively. The Y263F mutation is located within the C-terminal portion of the protein, which may be involved in folding of the substrate binding domain, and has a more modest effect on SIAH2 activity toward C/EBP␦. Expression in MDA-MB-231 cells showed that the same three mutants led to an increase in endogenous C/EBP␦ expression, suggesting a dominant negative effect of the SIAH2 mutants (Fig.  3M) . Collectively, these data indicate that tyrosines 86, 140, and 263 contribute to destabilization of C/EBP␦ and are targets of phosphorylation in the presence of Src activity.
SIAH2 interacts with C/EBP␦, leading to its polyubiquitination. To assess if SIAH2 was directly interacting with C/EBP␦, coimmunoprecipitation was performed in MDA-MB-468 cells. In fact, endogenous C/EBP␦ and SIAH2 were found in complex and at increased levels when the cells were treated with MG132, which stabilizes C/EBP␦ (Fig. 4A) . Next, we examined polyubiquitination of C/EBP␦ after immunoprecipitation of ectopic HAubiquitin from the tumor cell lines MDA-MB-468 and MDA-MB-231T. As shown in Fig. 4B , high-MW forms of C/EBP␦ were detected in MG132-treated cells unless a dominant negative SIAH2 had been cotransfected. These data demonstrate that C/EBP␦ is polyubiquitinated in an SIAH2-dependent manner in these breast tumor cell lines.
Polyubiquitination occurs commonly on lysine residues, which can also be sites of sumoylation (17) . The K120 residue of C/EBP␦ has been identified as a site of sumoylation (65) and was therefore a candidate site for ubiquitination. Indeed, a K120A mutation of C/EBP␦ prevented both Src-531-and SIAH2-mediated downregulation of C/EBP␦ in MCF-10A cells, while a nearby E122A mutation had no effect (Fig. 4C) . Although the K120A mutation protected C/EBP␦ from degradation, both the wild-type and K120A forms of C/EBP␦ were able to interact with ectopic SIAH2 in MCF-10A cells (Fig. 4D , left and right panels, respectively). However, the K120A mutation prevented C/EBP␦ polyubiquitination. WT-C/EBP␦ alone was relatively stable in MCF-10A cells ( Fig. 2A and B) and not significantly polyubiquitinated even in the presence of MG132 (Fig. 4E) . Ectopic SIAH2 caused polyubiquitination of WT-C/EBP␦, which accumulated in the presence of MG132. In contrast, no association of ubiquitin with the K120A mutant was detected in the presence of SIAH2 and MG132 (Fig. 4E ). These data demonstrate that the K120A residue of C/EBP␦ is necessary for the polyubiquitination and degradation of C/EBP␦ in response to Src/SIAH2 signaling even though it is not required for the interaction with SIAH2.
In order to identify the SIAH2 binding region of C/EBP␦, we performed coimmunoprecipitation experiments with different chimeric constructs of C/EBP␦ and C/EBP␤ (Fig. 5A ) because C/EBP␤ is not a target of SIAH2 (Fig. 1F and 4A) . Upon cotransfection with SIAH2 into MCF-10A cells, only proteins that contained amino acids (aa) 93 to 181 of C/EBP␦ (Fig. 5A, constructs 1,  3 , 4, and 7) were detected in immunoprecipitates of SIAH2. An internal deletion of aa 153 to 199 (64) did not impair the interaction with SIAH2, which further defined the interaction domain to aa 93 to 153 (data not shown). Within this domain, the conserved amino acids A137 and V139 align with the core of the consensus of SIAH substrate recognition motifs (Fig. 5B) , which further supports that this region is a bona fide SIAH2 interaction domain (25, 26) . Moreover, this sequence is not conserved in C/EBP␤, which did not undergo SIAH2-mediated degradation. Therefore, we introduced two individual point mutations into C/EBP␦ which change its sequence to that of C/EBP␤ (Fig. 5B) . The conservative V139A mutation did not impair the interaction of SIAH2 with C/EBP␦. Changing A137 to a tyrosine, as in the corresponding sequence of C/EBP␤, completely abolished interaction with SIAH2 (Fig. 5B) . Accordingly, A137Y-C/EBP␦ was protected from SIAH2-mediated downregulation in MCF-10A cells (Fig. 5C ). Taken together, these results demonstrate that SIAH2 directly in- teracts with C/EBP␦, which is necessary but not sufficient for its polyubiquitination and degradation.
Src/SIAH2-induced degradation of C/EBP␦ is necessary for cyclin D1 protein expression in breast tumor cell lines, cell motility, and invasion. We have previously shown that ectopic C/EBP␦ promotes degradation of cyclin D1 in breast tumor cell lines (47) . To address the physiological relevance of Src-mediated degradation of endogenous C/EBP␦, we assessed cyclin D1 expression in response to SKI-606. In agreement with previous reports (15, 69) , inhibition of Src family kinase activity in the MDA-MB-468 and MDA-MB-231T breast tumor cell lines resulted in reduced cyclin D1 expression ( Fig. 6A and B) . However, C/EBP␦ silencing by either transient (MDA-MB-468) or stable (MDA-MB231T) shRNA-mediated depletion attenuated inhibition of cyclin D1 expression by SKI-606 ( Fig. 6A and B) . As expected, loss of cyclin D1 in response to SKI-606 was accompanied by reduced phosphorylation of the cyclin D1/CDK4 substrate retinoblastoma protein (Rb) at S780 (Fig. 6B) . Given that phosphorylation of Rb1 contributes to inactivation of this tumor suppressor by dissociation from E2F transcription factors (2, 37) , the data suggest that SKI-606 may lead to activation of the Rb1 tumor suppressor pathway. However, when C/EBP␦ was silenced and cyclin D1 expression persisted in the presence of the Src kinase family inhibitor, Rb phosphorylation was also maintained (Fig. 6B) . These data demonstrate that degradation of endogenous C/EBP␦ by the Src pathway is necessary for high levels of cyclin D1 expression in these breast cancer cell lines and that stabilization of C/EBP␦ is necessary for SKI-606-induced inhibition of cyclin D1 expression and signaling.
SKI-606 at 1 M inhibits cell motility and invasion of breast tumor cell lines in vitro. Inhibition of cell growth appears to depend on cell lines and culture conditions (24, 32, 63) . In our hands, 1 M SKI-606 did not inhibit proliferation of MDA-MB-468 cells (Fig. 6C) or MDA-MB-231T cells with or without stable silencing of C/EBP␦ (Fig. 6D) . As expected, MDA-MB-231T cell motility in a wound closure assay was inhibited by SKI-606 (Fig.  6E) . However, when C/EBP␦ was silenced, SKI-606 was much less potent, and cells migrated even in the presence of SKI-606, i.e., in the absence of endogenous Src family kinase activity.
To further address the role of SIAH2 in the regulation of cell motility, we silenced SIAH2 in MDA-MB-231 cells and observed that, along with induced C/EBP␦ expression, cyclin D1 levels as well as Rb1 phosphorylation declined (Fig. 6H) . In addition, RNAi-mediated depletion of SIAH2 alone was sufficient to significantly reduce cell motility of MDA-MB-231T cells in the wound closure assay (Fig. 6H) . These data corroborate the role of SIAH2 in silencing the C/EBP␦ tumor suppressor pathway in this cancer cell line. Because cyclin D1 was also shown to promote cell motility (41, 73) , we overexpressed wild-type cyclin D1 and a degradationresistant cyclin D1 with a mutation of RK to EE (47) . As seen in Fig. 6I , ectopic cyclin D1 was sufficient to rescue cell motility in MDA-MB-231T cells in the presence of SKI-606. In fact, ectopic cyclin D1 alone was sufficient to promote cell motility (Fig. 6J ) and phosphorylation of Rb1 (Fig. 6K ) in MCF-10A cells. Ectopic wild-type cyclin D1 was expressed at lower levels than the degradation-resistant mutant (Fig. 6K ) but at levels sufficient for biological effects, most likely because endogenous factors for its degradation (47) are limiting. Consistently, we also observed lower levels of total Rb1 protein when cyclin D1 was overexpressed in MCF-10A cells. Collectively, these data show that C/EBP␦-dependent downregulation of cyclin D1 is an important event in the inhibition of cell motility in untransformed MCF-10A cells.
Next, we tested the effect of C/EBP␦ on more aggressive tumor cell properties such as migration through Matrigel and growth in soft agar. Similar to the results from the wound-healing assay (Fig.  6E) , knockdown of C/EBP␦ significantly reduced the ability of SKI-606 to prevent cell migration in a Matrigel transwell invasion assay (Fig. 6F ). In agreement with previous reports (63) SKI-606 also impaired the colony formation of MDA-MB-231T cells in soft agar (Fig. 6G) . Although SKI-606 still inhibited colony formation even when C/EBP␦ expression was silenced, significantly more colonies could still form (Fig. 6G) . Taken together, these data show that induction of C/EBP␦ expression augments the tumor cell response to SKI-606.
C/EBP␦ inhibits Src-mediated transformation of MCF-10A cells. Although cyclin D1 alone is not an oncogene, it can contribute significantly to cell transformation (41) . For these reasons we assessed the role of C/EBP␦ downregulation on oncogenic Src signaling in MCF-10A breast epithelial cells. Indeed, Src-531 induced expression of cyclin D1 and, as expected, downregulated ectopic WT-C/EBP␦ (Fig. 7A) . In contrast, the degradationresistant K120A-C/EBP␦ (Fig. 4C) or A137Y-C/EBP␦ (Fig. 5C ) prevented cyclin D1 induction and attenuated Rb phosphorylation despite the continued presence of Src-531 activity (Fig. 7A) . As shown before (Fig. 5C) , expression of SIAH2 alone in MCF-10A cells also downregulated wild-type but not mutant C/EBP␦. Consistent with our previous report (47) , downregulation of C/EBP␦ also resulted in elevated levels of cyclin D1 protein. However, phosphorylation of Rb was less pronounced in response to SIAH2 overexpression than Src-531 (Fig. 7A) .
Expression of oncogenic Src induces invasive properties of MCF-10A cells when grown in Matrigel (10). Typically, untransformed MCF-10A cells form hollow, spherical acini when plated in Matrigel (16), whereas transformed MCF-10A cells form lumina-filled acini due to the inhibition of apoptosis. Moreover, the transformed acini are not surrounded by an intact basement membrane, and there is invasion of cells into the Matrigel that requires Src activity (6, 10) . Wild-type SIAH2 is not known to be a driving oncogene. Indeed, ectopic SIAH2 expression in untransformed MCF-10A cells did not interfere with normal acinus formation (data not shown), possibly due to less effective Rb inactivation (Fig. 7A) and/or the absence of other oncogenes. In contrast, Src-531-expressing MCF-10A acini lost the hollow appearance, did not deposit basement membrane, and exhibited invasive properties (Fig. 7B and C) . Expression of K120A-C/EBP␦ but not WT-C/EBP␦ partially impaired the ability of Src-531 to drive invasive properties of MCF-10A cells in Matrigel. In the presence of K120A-C/EBP␦, Src-531-expressing MCF-10A cells formed only partially filled acini (Fig. 7B and C) . Staining for laminin 5 showed that K120A-C/EBP␦ as well as A137Y-C/EBP␦ restored basal deposition of basement membrane components by Src-531-transfected MCF-10A cells (Fig. 7C) . Src-531 caused a greater than 2-fold increase in the size of acini. However, there was no size difference between acini from WT-or K120A-transfected cells with or without Src (data not shown). Similarly, the number of acini was comparable between WT-and K120A-C/EBP␦- transfected MCF-10A cells with and without Src-531 (data not shown). However, instead of individual cells invading the Matrigel, the acini were distorted and more hollow (Fig. 7B and C) .
To further characterize the effect of C/EBP␦ on acinus formation of Src-531-expressing cells, we stained for the proliferation marker Ki67 and for active caspase-3 as an indicator of cell death.
In the absence of Src-531, 10-day-old acini were negative for Ki67 (data not shown). In the presence of Src-531, Ki67 was detected in all acini whether cotransfected with WT-C/EBP␦ or mutant C/EBP␦ (Fig. 7D) . After 14 days in culture, Ki67 staining persisted in WT-C/EBP␦ acini but was lost in the presence of mutant C/EBP␦ (data not shown). On the other hand, caspase-3 activity was detected in only K120A-C/EBP␦-or A137Y-C/EBP␦-expressing acini but not with WT-C/EBP␦ after both 10 days (Fig.  7D ) and 14 days of culture (data not shown). Thus, forced C/EBP␦ expression promotes anoikis of Src-531-expressing MCF-10A cells in Matrigel while having a more modest effect on cell proliferation. The latter may explain why there is no dramatic effect on the size of acini. These results are in agreement with a previously characterized proapoptotic activity of C/EBP␦ in vivo (61) .
In contrast to acinar growth on Matrigel, MCF-10A cells cannot form colonies in soft agar unless transformed by oncogenes, which permits anchorage-independent growth and is one of the features of transformed cells (21, 31) . When MCF-10A cells were transfected with Src-531, they were able to form colonies in soft agar. When stable K120A-C/EBP␦ or A137Y-C/EBP␦ was coexpressed with Src-531 instead of WT-C/EBP␦, significantly fewer colonies formed that were also smaller than controls (Fig. 7E) . Thus, C/EBP␦ that escapes downregulation by Src by either loss of SIAH2 interaction (A137Y) or resistance to polyubiquitination (K120A) interferes with full transformation of MCF-10A cells by Src. Collectively, these findings provide evidence that inhibition of C/EBP␦ expression is an important step for the induction of cyclin D1 expression and for complete transformation of breast tumor cell lines by Src signaling.
DISCUSSION
In this study we have identified a molecular mechanism by which C/EBP␦ protein is downregulated in breast tumor cells (Fig. 8) . We show that the Src kinase, which is frequently activated in can- cer, causes the tyrosine phosphorylation and activation of the SIAH2 E3 ubiquitin ligase, which in turn interacts with C/EBP␦, leading to polyubiquitination and proteasomal degradation of C/EBP␦. This pathway contributes to modulation of cell "transformation," a term that is used here to comprise enhanced cell migration and invasion, growth in soft agar, loss of basement membrane deposition, and reduced anoikis in vitro. Downregulation of C/EBP␦ protein was accompanied by upregulation of the pro-oncogenic protein cyclin D1 and concomitant phosphorylation of the tumor suppressor Rb1. Expression of C/EBP␦ interfered with MCF-10A cell transformation by a constitutively activated Src-531, and SKI-606-induced C/EBP␦ expression in breast tumor cells contributed to the drug's effect on invasive properties such as cell motility, transwell migration, and growth in soft agar. Collectively, these data support a tumor suppressor-like function for C/EBP␦ in human breast epithelial cells, which modulates the cellular response to Src kinase activity. Previously, we reported that C/EBP␦ inhibits expression of the tumor suppressor FBXW7, which leads to activation of the AKT/mTOR/HIF-1 pathway specifically under hypoxia when C/EBP␦ expression is induced (7) . Both hypoxia and the mTOR/AKT pathway promote tumor progression (59) . In fact, C/EBP␦ null mice exhibit higher Erbb2-Neu-induced mammary tumor incidence but reduced lung metastasis, suggesting that C/EBP␦ can act as both a tumor suppressor and tumor promoter (7) . Given that these results were obtained with mice carrying a germ line mutation of C/EBP␦, both activities could be due to functions in tumor cells and/or cells of the tumor environment. The data reported in the present study support a tumor suppressor-like function of C/EBP␦ within breast epithelial cells under normoxic conditions. As both Src and SIAH are activated under hypoxia (19, 27) , we hypothesize that hypoxia provides additional signals that prevent SIAH-mediated C/EBP␦ degradation and may also modulate the downstream effects of C/EBP␦.
We began this study with the hypothesis that Src regulates the C/EBP␦ gene promoter. In transient cotransfection experiments activated Src, indeed, inhibited a C/EBP␦ promoter-reporter construct. Thus, we do not rule out that Src can also inhibit C/EBP␦ transcription, perhaps through activation of c-myc (72) . However, we show that regulation of protein stability is an important mechanism controlling C/EBP␦ expression levels in breast tumor cell lines, which acts subsequent to any regulation of promoter activity. A previous report had shown that C/EBP␦ is degraded by the proteasome in vitro but suggested that this was ubiquitin independent (74) . The same study reported a short half-life (120 min) for C/EBP␦ in growth-arrested HC11 mouse mammary epithelial cells although C/EBP␦ expression is in fact induced at G 0 (74) . In contrast, we found that C/EBP␦ was rather stable in untransformed MCF-10A cells and that the SIAH2 E3 ligase and polyubiquitination were necessary for reduced C/EBP␦ protein levels in human breast tumor cell lines. Among C/EBP family members, this is a unique pathway because the A137 residue of C/EBP␦, which was necessary for interaction with SIAH2, is replaced by tyrosine or phenylalanine in other C/EBP proteins. To our knowledge, among C/EBP proteins, ubiquitin-mediated degradation has been reported only for C/EBP␣ via interaction with FBXW7 (9, 57), which-as mentioned above-is a C/EBP␦ repressed gene (7) . SIAH ubiquitin ligases can require cofactors for interaction with and targeting of substrates (55, 68) , and substrate interaction may depend on extracellular signals, such as EGF, as described for the substrate PLC (70) . We found that the K120 residue of C/EBP␦ was necessary for its polyubiquitination. Given that we have not demonstrated polyubiquitination at K120 directly, other explanations for the phenotype of the K120A mutation could be loss of phosphorylation or cofactor interaction necessary for ubiquitination at other lysine residues.
Previous studies showed that K120 was necessary for sumoylation of C/EBP␦ and its interaction with HDAC1 and HDAC3 to repress gene expression (65) . In our experiments, K120A-C/EBP␦ was able to downregulate cyclin D1 expression and to partially prevent Src-531 transformation of MCF-10A cells. Therefore, we conclude that sumoylation at K120 is not necessary for these tumor suppressor-like activities. However, sumoylation or acetylation at K120 could be a physiological mechanism to prevent C/EBP␦ degradation. Given that C/EBP␦ expression is often only transiently induced by various stimuli, we speculate that protein (de)stabilization may play a significant role in other cellular systems such as the inflammatory response (51) or hypoxia (7) .
Destabilization of C/EBP␦ in breast epithelial cells was dependent on Src kinase signaling. While ectopic Src-531 in MCF-10A cells mimicked many of the activities attributed to SKI-606-inhibited kinase activities in tumor cell lines, it is very likely that other Src family kinases may also contribute to C/EBP␦ degradation. This will probably depend on the ability of such other kinases to induce expression and/or activity of the SIAH2 ligase or other necessary cofactors. Also, it remains to be determined why SIAH2 overexpression was sufficient to downregulate C/EBP␦ in MCF-10A cells even though these cells do not exhibit significant levels of endogenous phosphorylated Src kinases. Possibly, the transient lower levels of endogenous Src family kinase activity are sufficient for activation of SIAH2, or other kinases that alone do not induce expression of endogenous SIAH2 can contribute to its catalytic activation, such as p38 mitogen-activated protein kinase (MAPK) (34) . We found that activated Src phosphorylated SIAH2 in vitro FIG 8 Schematic summarizing the molecular pathway described in this study.
Activated Src kinase, which can be inhibited by SKI-606, induces expression and/or activity (P, phosphorylation) of the SIAH2 E3 ligase. SIAH2 interacts with C/EBP␦ and promotes its polyubiquitination (Ub) and proteasomal degradation (19S/20S depict the proteasome). In the presence of C/EBP␦, cyclin D1 becomes downregulated, and cells exhibit less "transformed" features, such as reduced motility and invasion in two-dimensional cultures, less invasive acini and anoikis in three-dimensional cultures, and reduced colony formation in soft agar.
on three tyrosines, each of which contributes to SIAH2 activity in vivo. It remains to be determined if Src and/or other Src family kinases mediate the direct activation of SIAH2 in vivo and how the tyrosine phosphorylations functionally interact with SIAH2 activation by p38 MAPK (34) .
In animal and xenograft models, SIAH2 was characterized as a tumor promoter (4, 27, 50, 56) . A recent report using SIAH2-specific immunostaining showed that SIAH2 is most highly expressed in advanced, basal-like breast cancer due to gene amplification (14) . Similarly, cytoplasmic Src family kinase activity is associated with more aggressive breast cancer and also shorter patient survival (19) . In vitro data support the notion that this may be due to the promotion of invasive features by Src (54) and is in part mediated by elevated levels of cyclin D1 (41) . We found that downregulation of C/EBP␦ augmented Src-induced cyclin D1 protein expression in breast tumor cell lines. We previously reported that C/EBP␦ promotes cyclin D1 degradation through upregulation of Cdc27/APC3 expression (47). We do not rule out that transcriptional mechanisms contributed to the cyclin D1 regulation observed in the present study. However, even when cyclin D1 mRNA levels are high, continued expression of C/EBP␦ may promote cyclin D1 degradation (47) . Cyclin D1 is overexpressed in different cancers, including breast, and many studies have associated cyclin D1 with malignant cell features and tumor progression (35) including cell motility (41) . In some reports, cyclin D1 was associated with reduced cell migration and more favorable prognosis (39) , which may depend on other cofactors such as splice variants and availability of p27 KIP1 (40) . Thus, the precise role of cyclin D1 downregulation in inhibition of cell transformation by C/EBP␦ signaling remains to be determined.
Lastly, SKI-606 (bosutinib) shows very promising activity in clinical and preclinical trials (12) . Our results raise the possibility that C/EBP␦ and its downstream mediators may be critical for therapeutic response and that further investigations into this pathway could lead to the identification of predictive biomarkers.
In conclusion, this study revealed a novel signaling pathway, which links Src kinase(s), the SIAH2 E3 ubiquitin ligase, and the C/EBP␦ transcription factor and shows that this pathway contributes to transformed features of breast epithelial cell lines.
